Melanoma-Pipeline Review, H2 2018
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Melanoma-Pipeline Review, H2 2018, provides an overview of the Melanoma (Oncology) pipeline landscape.
Melanoma is a tumor that develops as a result of the malignant transformation of melanocytes. These cells are derived from the neural crest. Melanomas usually occur on the skin but can arise in other locations where neural crest cells migrate, such as in the gastrointestinal tract or brain. It is more common in women than in men. In women, the most common site is the legs and melanomas in men are most common on the back. Unusual moles, sores, lumps, blemishes, markings, or changes in the way an area of the skin looks or feels are sign of melanoma. Treatment includes surgery, radiation and proton therapy.
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Melanoma-Pipeline Review, H2 2018, provides comprehensive information on the therapeutics under development for Melanoma (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Melanoma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Melanoma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, Phase 0, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 3, 1, 18, 126, 141, 1, 11, 223, 33 and 4 respectively. Similarly, the Universities portfolio in Phase III, Phase II, Phase I, Preclinical and Discovery stages comprises 2, 18, 16, 75 and 11 molecules, respectively.
Melanoma (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
- The pipeline guide provides a snapshot of the global therapeutic landscape of Melanoma (Oncology).
- The pipeline guide reviews pipeline therapeutics for Melanoma (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Melanoma (Oncology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Melanoma (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Melanoma (Oncology)
Reasons to buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Melanoma (Oncology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Melanoma (Oncology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
Table of Contents 2
Melanoma-Therapeutics Development 14
Melanoma-Therapeutics Assessment 80
Melanoma-Companies Involved in Therapeutics Development 114
Melanoma-Drug Profiles 240
Melanoma-Dormant Projects 2161
Melanoma-Discontinued Products 2195
Melanoma-Product Development Milestones 2200
List of Figures
Number of Products under Development for Melanoma, H2 2018 85
Number of Products under Development by Companies, H2 2018 86
Number of Products under Development by Universities/Institutes, H2 2018 107
Number of Products by Top 10 Targets, H2 2018 151
Number of Products by Stage and Top 10 Targets, H2 2018 151
Number of Products by Top 10 Mechanism of Actions, H2 2018 166
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2018 166
Number of Products by Routes of Administration, H2 2018 181
Number of Products by Stage and Routes of Administration, H2 2018 181
Number of Products by Top 10 Molecule Types, H2 2018 183
Number of Products by Stage and Top 10 Molecule Types, H2 2018 183
List of Tables
Number of Products under Development for Melanoma, H2 2018 85
Number of Products under Development by Companies, H2 2018 87
Number of Products under Development by Universities/Institutes, H2 2018 108
Products under Development by Companies, H2 2018 113
Products under Development by Universities/Institutes, H2 2018 144
Number of Products by Stage and Target, H2 2018 152
Number of Products by Stage and Mechanism of Action, H2 2018 167
Number of Products by Stage and Route of Administration, H2 2018 182
Number of Products by Stage and Molecule Type, H2 2018 184
Melanoma-Pipeline by 4D Pharma PLC, H2 2018 185
Melanoma-Pipeline by 4P-Pharma SAS, H2 2018 185
Melanoma-Pipeline by 4SC AG, H2 2018 186
Melanoma-Pipeline by AB Science SA, H2 2018 186
Melanoma-Pipeline by AbbVie Inc, H2 2018 187
Melanoma-Pipeline by Abivax SA, H2 2018 187
Melanoma-Pipeline by Adaptimmune Therapeutics Plc, H2 2018 188
Melanoma-Pipeline by Aduro BioTech Inc, H2 2018 188
Melanoma-Pipeline by Advanced BioDesign, H2 2018 189
Melanoma-Pipeline by Advenchen Laboratories LLC, H2 2018 189
Melanoma-Pipeline by Aeglea BioTherapeutics Inc, H2 2018 190
Melanoma-Pipeline by Afecta Pharmaceuticals Inc, H2 2018 190
Melanoma-Pipeline by Affichem SA, H2 2018 190
Melanoma-Pipeline by Agenus Inc, H2 2018 191
Melanoma-Pipeline by AGV Discovery SAS, H2 2018 191
Melanoma-Pipeline by AIMM Therapeutics BV, H2 2018 192
Melanoma-Pipeline by AiVita Biomedical Inc, H2 2018 192
Melanoma-Pipeline by Alkermes Plc, H2 2018 193
Melanoma-Pipeline by Allergy Therapeutics Plc, H2 2018 193
Melanoma-Pipeline by Alligator Bioscience AB, H2 2018 194
Melanoma-Pipeline by Altor BioScience Corp, H2 2018 194
Melanoma-Pipeline by Amgen Inc, H2 2018 195
Melanoma-Pipeline by Angimmune LLC, H2 2018 195
Melanoma-Pipeline by Antibe Therapeutics Inc, H2 2018 196
Melanoma-Pipeline by APEIRON Biologics AG, H2 2018 196
Melanoma-Pipeline by Apexigen Inc, H2 2018 196
Melanoma-Pipeline by Aphios Corp, H2 2018 197
Melanoma-Pipeline by Aposense Ltd, H2 2018 197
Melanoma-Pipeline by Aprea AB, H2 2018 198
Melanoma-Pipeline by Aptose Biosciences Inc, H2 2018 198
Melanoma-Pipeline by Arcus Biosciences Inc, H2 2018 199
Melanoma-Pipeline by ArQule Inc, H2 2018 199
Melanoma-Pipeline by Array BioPharma Inc, H2 2018 200
Melanoma-Pipeline by Asana BioSciences LLC, H2 2018 200
Melanoma-Pipeline by Ascentage Pharma Group Corp Ltd, H2 2018 201
Melanoma-Pipeline by Astex Pharmaceuticals Inc, H2 2018 201
Melanoma-Pipeline by Atreca Inc, H2 2018 201
Melanoma-Pipeline by aTyr Pharma Inc, H2 2018 202
Melanoma-Pipeline by Aurigene Discovery Technologies Ltd, H2 2018 202
Melanoma-Pipeline by Autolus Therapeutics Plc, H2 2018 203
Melanoma-Pipeline by Basilea Pharmaceutica Ltd, H2 2018 203
Melanoma-Pipeline by Batu Biologics Inc, H2 2018 204
Melanoma-Pipeline by Bayer AG, H2 2018 204
Melanoma-Pipeline by BeiGene Ltd, H2 2018 205
Melanoma-Pipeline by Beijing Kawin Technology Share-Holding Co Ltd, H2 2018 205
Melanoma-Pipeline by Bellicum Pharmaceuticals Inc, H2 2018 206
Melanoma-Pipeline by BerGenBio ASA, H2 2018 206
Single User License:
Corporate User License:
4D Pharma PLC
AB Science SA
Adaptimmune Therapeutics Plc
Aduro BioTech Inc
Advenchen Laboratories LLC
Aeglea BioTherapeutics Inc
Afecta Pharmaceuticals Inc
AGV Discovery SAS
AIMM Therapeutics BV
AiVita Biomedical Inc
Allergy Therapeutics Plc
Alligator Bioscience AB
Altor BioScience Corp
Antibe Therapeutics Inc
APEIRON Biologics AG
Aptose Biosciences Inc
Arcus Biosciences Inc
Array BioPharma Inc
Asana BioSciences LLC
Ascentage Pharma Group Corp Ltd
Astex Pharmaceuticals Inc
aTyr Pharma Inc
Aurigene Discovery Technologies Ltd
Autolus Therapeutics Plc
Basilea Pharmaceutica Ltd
Batu Biologics Inc
Beijing Kawin Technology Share-Holding Co Ltd
Bellicum Pharmaceuticals Inc
Bio-Cancer Treatment International Ltd
Biohaven Pharmaceutical Holding Company Ltd
Biothera Pharmaceutical Inc
BioXcel Therapeutics Inc
Boehringer Ingelheim GmbH
Boston Biomedical Inc
BrightPath Biotherapeutics Co Ltd
Bristol-Myers Squibb Co
Calithera Biosciences Inc
Can-Fite BioPharma Ltd
CBT Pharmaceuticals Inc
Celdara Medical LLC
Celldex Therapeutics Inc
Cellestia Biotech AG
Checkmate Pharmaceuticals Inc
Checkpoint Therapeutics Inc
Chipscreen Biosciences Ltd
Chugai Pharmaceutical Co Ltd
Constellation Pharmaceuticals Inc
Corvus Pharmaceuticals Inc
Cue Biopharma Inc
CytomX Therapeutics Inc
Cytori Therapeutics Inc
CZ BioMed Corp
Daiichi Sankyo Co Ltd
Debiopharm International SA
Deciphera Pharmaceuticals LLC
Dynavax Technologies Corp
Eisai Co Ltd
Eli Lilly and Co
Elsalys Biotech SA
Emcure Pharmaceuticals Ltd
eTheRNA Immunotherapies NV
Evelo Biosciences Inc
select a license
NEWSLETTER BY CATEGORY
The report was very informative and gives me an interesting view on the Indian market.... "Area Sales Manager, Muhlen Sohn GmbH & Co. KG"
We would like to thank the entire team of Ken Research in showcasing professionalism in research and quick turnaround time. We have had multiple research reports from Ken Research. The deadline communicated for research was duly met. The research reports were covering many aspects in detail. This showcases their endeavor and care for client satisfaction and a strong understanding of the clients’ requirements. Thank you again for your help... "Group Vice President Strategy, Aliaxis"
I appreciate their diligence and determination in customizing the research project. The data proves to be valuable and accurate. I would, in future, definitely use their services again... "Technical Marketing Manager, Ascendis Health Limited"
I would like to thank Ken research team for meeting our report deliverables. The report is very good and we appreciate your well cooperation. ... "., Coldwell Banker - Riyadh "
The research you conducted was very helpful for us and the integrity of your research approach gave us great confidence in the data. Look forward to collaborating again in future... "International and Business Dev. Director, Duta Abadi Primantara"